# 2 HORMONAL PHASE‑ALIGNED SYSTEM

Source: https://femstate.me/docs/2-hormonal-phase-aligned-system.md · Updated: 2026-09-10

---

1
HORMONAL PHASE‑ALIGNED HORMONE RECEPTOR‑POSITIVE‑SAFE
NUTRACEUTICAL SYSTEM AND METHOD OF PROVIDING SAME
FIELD OF THE INVENTION
[0001] The application relates to compositions, a system, and kit for providing hormonalphased aligned timed dietary supplement. Specifically, the application relates to hormone‑neutral, female hormonal phase‑aligned nutraceutical compositions, kits containing the same, and compliance‑oriented packaging designed to adapt to a woman’s changing physiological needs.
BACKGROUND
[0002] Most nutritional supplements are based on biomedical research that suggests providing one formula, every day, for everyone. However, women experience natural physiological changes
(or cycles) over time, which can influence their metabolism, energy, recovery, mood, sleep, skin health, and nutrient utilization. It is for this very reason that much of the research excludes women from its test subjects. So, many women find themselves taking multiple supplements, following advice designed for the general population, experimenting through trial and error, and feeling overwhelmed by conflicting wellness information.
[0003] Indeed, it has been found that the female endocrine system is a highly coordinated biological network responsible for regulating reproduction, metabolism, immune function, neurological activity, cardiovascular health, musculoskeletal integrity, and numerous aspects of physical and psychological well-being. Unlike many physiological systems that maintain relatively stable homeostasis over time, the female endocrine system is characterized by predictable, cyclical hormonal fluctuations that produce measurable changes in cellular function, organ physiology, nutrient metabolism, and behavioral responses throughout the reproductive lifespan. These changes begin during puberty, continue through the reproductive years, gradually transition during perimenopause, and ultimately stabilize following menopause.
2
[0004] Although the clinical significance of these changes varies among individuals, it is becoming accepted that during their reproductive years, there are distinct phases of the female hormonal cycle which are associated with characteristic physiological environments that may influence nutritional requirements, exercise tolerance, cognitive performance, and symptom presentation. These phases have been commonly defined as the menstrual, follicular, ovulatory, and luteal cycles.
[0005] But, existing nutritional supplement products often do not account for these phasedependent physiological changes and instead provide substantially uniform formulations throughout the menstrual cycle. Other products may incorporate botanical ingredients, phytoestrogens, hormone precursors, or other compounds capable of interacting with estrogenic, progestogenic, or other hormone-related pathways.
[0006] Such approaches may not be appropriate for all individuals. In particular, individuals with a history of, or increased risk for, (HR+) cancers may be advised to exercise caution with ingredients having potential hormonal or hormone-modulating activity. HR+ cancers express receptors for hormones such as estrogen and/or progesterone, and activation of these signaling pathways can promote the growth of certain hormone-sensitive cancer cells.
[0007] Accordingly, there remains a need for nutritional systems that account for phasedependent changes in female physiology while providing nutritional support without requiring exogenous hormones or ingredients selected for the purpose of mimicking estrogen or progesterone.
SUMMARY
[0008] A method of providing female hormonal phase aligned nutritional support is provided.
In one embodiment, the method includes (a) providing a plurality of orally ingestible nutraceutical
3
compositions; wherein each of the compositions is configured to be taken during a phase of a user’s menstrual cycle, the phases comprising a menstrual phase, a follicular phase, an ovulation phase, and a luteal phase; providing instructions for the administration of the plurality of compositions on a predetermined schedule; wherein the schedule is configured to correspond to the four phases of the menstrual cycle, wherein each composition comprises at least one mineral, vitamin, amino acid or carotenoid in an amount effective to promote phase aligned wellbeing, with magnesium present in a range of 100–300 mg elemental per dose, and each composition being free of phyto‑estrogenic or progesterone‑modulating botanicals, and wherein each composition is provided in a powder, capsule, softgel, or night‑time beverage form and chosen for bioavailability optimization.
[0009] In one embodiment, the predetermined cycle is 28 days and the schedule instructs the user to administer a first composition corresponding to the menstrual phase on cycle days 1-5, a second composition corresponding to the follicular phase on cycle days 6-13, a third composition corresponding to the ovulation phase on cycle days 14-17, and a fourth composition corresponding to the luteal phase on cycle days 18-28.
DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 is a graphical representation of a standard 28 day administration schedule correlating to four distinct hormonal phases of the menstrual cyle;
[0011] Figure 2 is a front view of one embodiment of a stackable pod for use with the compositions of the present application;
[0012] Figure 3 is a graphical representation of an example user interface for use with an embodiment of the system provided herein;
4
[0013] Figure 4 is a graphical representation of eight hormone curves and associated menstrual phases; and
[0014] Figure 5 is a graphical representation of correlation between the hormonal changes of a user and the associated nutraceutical formulations.
DETAILED DESCRIPTION
[0015] A cycle-specific nutraceutical system, kit and method that delivers HR+-safe compositions is configured to be administered over a predetermined administration schedule timed to the user’s menstrual (M), follicular (F), ovulatory (O), and luteal (L) phases, as shown in Figure
1. Each composition is formulated to be expressly devoid of phyto-estrogenic or
progesterone-modulating botanicals and is provided in a delivery format optimized for bioavailability, such as a powder, gel, tablet, injection, sachets, capsules, liquid, or other suitable pharmaceutically acceptable formulation.
[0016] In one example, visually-distinct, stackable pods 10, as shown in Figure 2, cue a user’s compliance. In this embodiment, the lids 12 of the stackable pods 10 (or containers) may vary in color depending on the associated phase (M, F, O, L). For example, a purple lid 12 on the pod body 14 could indicate that the formulation inside corresponds to the menstrual phase, an orange lid 12 may indicate that the formulation corresponds to the follicular lid, a pink lid 12 may indicate that the formulation corresponds to the ovulatory phase, and a teal lid 12 may indicate that the formulation corresponds to the luteal phase. The pods 10 may include commercially acceptable desiccants 16 or other ingredients designed to maintain the viability of the formulation within. In another embodiment, as shown in Figure 3, an optional software gate may be designed to unlock booster pods upon medical or algorithmic clearance or to automatically adjust the user’s schedule based on algorithmic inputs and data or AI-directed dispensing instructions. In one embodiment,
5
a software program may be used to implement an adaptive dispensing model based on a user’s physiological state. For example, the system may provide formulation selection based on one or more physiological signals, including: menstrual onset, estimated endocrine phase, hormonal biomarkers, LH surge, ovulation confirmation, basal body temperature, wearable-derived physiological data, heart-rate variability, sleep metrics, laboratory biomarkers, user-reported physiological inputs, and predictive algorithms.
[0017] In one embodiment, a set of four nutritional supplements are provided. Each of the four formulations is designed to correspond to a distinct cycle or phase of a female user’s reproductive cycle. The menstrual cycle generally begins on the first day of the menstrual bleeding and concludes immediately before the onset of the subsequent menstrual cycle. In healthy reproductive-aged women, cycle length typically ranges between 24 and 38 days, with modest variation both between individuals and from cycle to cycle. Although the 28-day cycle is frequently used for educational purposes and provides a useful framework for describing endocrine physiology, it should not be interpreted as the only normal cycle length. Professional organizations recognize substantial physiological variability among healthy women, and ovulation may occur on different cycle days depending on individual endocrine regulation. In other embodiments, the menstrual cycle may be of varying durations, including but not limited to: 21-day cycles, 24-day cycles, 26-day cycles, 28-day cycles, 30-day cycles, 32-day cycles, 35-day cycles and include irregular cycles, algorithmically predicted cycles, and biomarker-confirmed cycles.
[0018] The four supplement formulations may be dynamically adjusted to the physiological phases of the user rather than a fixed calendar schedule.
[0019] It has been found that rather than progressing as a continuous uniform process, the menstrual cycle consists of four functionally distinct physiological phases:
6
1. Menstrual Phase: characterized by endometrial shedding and initiation of tissue
repair. It typically begins on the first day of menstruation.
2. Follicular Phase: characterized by follicular recruitment, increasing estradiol
production, cellular proliferation, and endometrial regeneration. It is typically defined as beginning on the sixth day of menstruation and ends with ovulation.
3. Ovulatory Phase: characterized by the luteinizing hormone surge, ovulation,
localized inflammatory remodeling, and transition to luteal physiology. This typically happens between 14-18 days after the beginning of the menstrual phase, and may be pinpointed with suitable hormonal testing.
4. Luteal Phase: characterized by progesterone dominance, corpus luteum activity,
endometrial differentiation, and preparation for potential implantation. The luteal phase extends from the end of ovulation until the onset of menstruation.
[0020] Each phase is defined not only by characteristic hormonal profiles (as shown in Figure
4 and below in Table I) but also by distinct biological priorities that influence multiple physiological systems as shown in Table II.
TABLE I
Phase Estradiol Progesterone LH FSH Testosterone
RESET™ Low Low Basal Early follicular rise Low-normal
LIFT™ Rising Low Basal Gradual decline Slight increase
SHINE™ Peak Beginning to rise LH surge Secondary surge Mild periovulatory peak
SOOTHE™ Moderate Peak Basal Suppressed Baseline
7
TABLE II
Phase
Cycle Days
(28-day embodiment)
Estradiol
(pg/mL)
Progesterone
(ng/mL)
LH
(IU/L) FSH (IU/L) Testosterone
(ng/dL)
Biological
Environment
RESET Days 1–5 20–80 <1.0 2–10 3–10 15–50
Tissue regeneration, endometrial shedding, immune remodeling
LIFT Days 6–13
80–
300(progressi vely rising)
0.3–1.5 2–12
3–
10(gradually declining)
20–70
Follicular growth, anabolic metabolism, cellular proliferation
SHINE Days 13–15 200–
500(peak) 1–3
20–
100(surg e)
6–
20(secondar y surge)
30–80(modest peak)
Ovulation, mitochondrial activation, extracellular matrix remodeling
SOOTHE Days 16–28 80–250 5–20 (midluteal peak) 1–10 1–8 20–60
Neuroendocri ne regulation, metabolic stabilization, physiological recovery
[0021] The hormone concentrations presented herein are representative physiological ranges for healthy reproductive-aged women and are intended to illustrate relative endocrine environments.
Actual concentrations vary according to individual physiology, laboratory methodology, age, body composition, circadian rhythm, and cycle characteristics. It should be appreciated that the hormone levels may change, depending on the age and health of the user. For example, the hormone levels, and therefore the phase designations may change for adolescents, those in perimenopause and menopause, for those using hormonal contraception, those who are postpartum, etc.
8
[0022] Each phase has been found to be associated with characteristic changes in circulating reproductive hormones, including estrogen and progesterone, as well as corresponding changes in metabolic, nutritional, inflammatory, neurological, and other physiological processes.
[0023] For example, and referring again to Figure 4, it has been found that during the menstrual phase, a woman’s body focuses on restoration. Therefore, her body benefits from added support for recovery, including iron replenishment, inflammation support, and mineral restoration. During the follicular phase, as estrogen naturally rises, many women shift toward growth, recovery, and activity. During the ovulatory phase, support for cellular protection is important. Therefore support for skin health, antioxidants, energy, metabolism, and mitochondrial support have been found to be beneficial. And, during the luteal phase, as progesterone changes, many women experience different nutritional priorities. Therefore, support for relaxation, magnesium health, neurotransmitter, and digestive support is at a premium. Rather than replacing or mimicking the hormones produced throughout other phases of a woman’s cycle, it has been found that providing support for what her body needs, when she needs it most, may be most beneficial, as shown below:
9
[0024] Therefore, in one embodiment, a first phase-aligned nutraceutical formulation is provided that corresponds with the nutritional needs of a user during her menstrual phase
(Referring again to Figure 4 and Figure 5). This first phase-aligned formulation may be a reset formulation to be taken on days 1-5 of a 28 standard day cycle. A second phase-aligned formulation, or a lift formulation, may be taken during days 6-13 of the user’s cycle, corresponding to the follicular phase. A third phase-aligned formulation, a shine formulation, may be taken during days 14 (+/- 1 day) of the user’s cycle, corresponding to the ovulatory phase. And, a fourth phase-aligned formulation, a soothe formulation, may be taken during days 14/16-28 of the user’s cycle, corresponding to the luteal phase. It should be understood that each individual user’s hormonal cycles may be different. Therefore, the cycle days and lengths may change depending upon individual guidance.
[0025] The formulations may include combinations of vitamins, minerals, amino acids and neuroactives, botanicals, and structural and metabolic ingredients that are designed to support each phase of a woman’s cycle.
10
[0026] In one embodiment, the vitamins may include vitamins A, C, D (D3), E, B12, B6, K2,
Thiamin, Riboflavin, Niacin, Folate, Pantothenic Acid, and combinations of the same. Mineral additives may include magnesium glycinate, magnesium bisglycinate, iron, zinc, selenium, chromium, potassium, and sodium. Amino acids and neuroactives suitable for use in the formulations include L-Theanine, L-tryptophan, GABA, and myo-inositol. Suitable botanicals include ginger, tart cherry, broccoli sprout extract (sulforaphane source), chamomile, saffron, resveratrol, and quercetin. Structural and metabolic ingredients may include CoQ10, Hyaluronic acid, astaxanthin, ceramides, inulin, and probiotics. One example of the individual formulations may be found below in Table III.
11
TABLE III
*each ingredient may be present in the formulation +/- 40% of the amount provided.
[0027] In another embodiment, a method of administering four distinct HR+ safe compositions during pre‑set calendar windows is provided. The method may include determining the structure of the user’s menstrual cycle, i.e. the length of each phase (menstrual, follicular, ovulation, and
12
luteal) of a user’s cycle; providing four orally ingestible nutraceutical compositions that correspond to each phase of the user’s menstrual cycle; and providing instructions for administering each nutraceutical composition during the corresponding phase.
[0028] Specific color codes, dose values and ingredient lists herein are exemplary; functional equivalents and therapeutically effective ranges remain within the contemplated scope except where expressly limited in the claims.
[0029] The terminology used herein is for the purpose of describing particular implementations only and is not intended to be limiting of the claims. As used in the description of the implementations and the appended claims, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will also be understood that the term “and/or” as used herein refers to and encompasses any and all possible combinations of one or more of the associated listed items. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.
[0030] As used herein, the term “if” may be construed to mean “when” or “upon” or “in response to determining” or “in accordance with a determination” or “in response to detecting,”
that a stated condition precedent is true, depending on the context. Similarly, the phrase “if it is determined [that a stated condition precedent is true]” or “if [a stated condition precedent is true]”
or “when [a stated condition precedent is true]” may be construed to mean “upon determining” or
“in response to determining” or “in accordance with a determination” or “upon detecting” or “in response to detecting” that the stated condition precedent is true, depending on the context.
13
[0031] The foregoing description and summary of the invention are to be understood as being in every respect illustrative and exemplary, but not restrictive, and the scope of the invention disclosed herein is not to be determined only from the detailed description of illustrative implementations but according to the full breadth permitted by patent laws. It is to be understood that the implementations shown and described herein are only illustrative of the principles of the present invention and that various modifications may be implemented by those skilled in the art without departing from the scope and spirit of the invention.
14
CLAIMS
1. A method of providing female hormonal phase aligned nutritional support comprising:
(a) providing a plurality of orally ingestible nutraceutical compositions; wherein each of the compositions is configured to be taken during a phase of a user’s menstrual cycle, the phases comprising a menstrual phase, a follicular phase, an ovulation phase, and a luteal phase;
(b) providing instructions for the administration of the plurality of compositions on a predetermined schedule; wherein the schedule is configured to correspond to the four phases of the menstrual cycle;
(c) wherein each composition comprises at least one mineral, vitamin, amino acid or carotenoid in an amount effective to promote phase aligned wellbeing, with magnesium present in a range of 100–300 mg elemental per dose, and each composition being free of phyto‑estrogenic or progesterone‑modulating botanicals; and
(d) wherein each composition is provided in a powder, capsule, softgel, or night‑time beverage form and chosen for bioavailability optimization.
2. The method of claim 1, wherein the predetermined cycle is 28 days and the schedule
instructs the user to administer a first composition corresponding to the menstrual phase on cycle days 1-5, a second composition corresponding to the follicular phase on cycle days 6-13, a third composition corresponding to the ovulation phase on cycle days 14-17, and a fourth composition corresponding to the luteal phase on cycle days 18-28.
3. The method of claim 1, wherein the composition corresponding to the menstrual phase
comprises about 150–300 mg elemental magnesium, about 12–24 mg iron , about 200–400 mg vitamin C , about 100–300 mg curcumin, and about 20–60 mg sulforaphane.
15
4. The method of claim 1, wherein the composition corresponding to the luteal phase
comprises about 150–250 mg elemental magnesium L-threonate , about 150–300 mg theanine, and about 20–30 mg saffron extract.
5. A nutraceutical kit comprising:
(a) at least four stackable pods, each pod comprising a formulation corresponding to a menstrual, follicular, ovulation, and luteal phase of a woman’s menstrual cycle; wherein each composition comprises at least one mineral, vitamin, amino acid or carotenoid in an amount effective to promote phase aligned wellbeing, with magnesium present in a range of 100–300 mg elemental per dose, and each composition being free of phyto-estrogenic or progesterone-modulating botanicals, and
(b) each pod having a lid bearing a hue visually distinguishable from the lids of the other pods, the hues corresponding respectively to menstrual, follicular, ovulatory and luteal phases of the user’s menstrual cycle.
6. The kit of claim 5, wherein the formulation corresponding to the menstrual phase
comprises about 150–300 mg elemental magnesium, about 12–24 mg iron , about 200–400 mg vitamin C , about 100–300 mg curcumin, and about 20–60 mg sulforaphane.
7. The kit of claim 5, wherein the formulation corresponding to the luteal phase comprises
about 150–250 mg elemental magnesium L-threonate , about 150–300 mg theanine, and about 20–
30 mg saffron extract.
8. The kit of claim 5, wherein the lid hues are red, teal, coral and lavender, respectively.
9. The kit of claim 8, wherein the red hue is within ±5 ΔE of Pantone 186 C, the teal hue
within ±5 ΔE of Pantone 326 C, the coral hue within ±5 ΔE of Pantone 177 C and the lavender hue within ±5 ΔE of Pantone 7650 C.
16
10. A supplementation system comprising the kit of claim 3 and a mobile software application
configured to selectively unlock an optional booster pod containing a hormone‑active botanical only upon verified medical clearance.
17
ABSTRACT
A method of providing female hormonal phase aligned nutritional support is provided. In one embodiment, the method includes (a) providing a plurality of orally ingestible nutraceutical compositions; wherein each of the compositions is configured to be taken during a phase of a user’s menstrual cycle, the phases comprising a menstrual phase, a follicular phase, an ovulation phase, and a luteal phase; providing instructions for the administration of the plurality of compositions on a predetermined schedule; wherein the schedule is configured to correspond to the four phases of the menstrual cycle, wherein each composition comprises at least one mineral, vitamin, amino acid or carotenoid in an amount effective to promote phase aligned wellbeing, with magnesium present in a range of 100–300 mg elemental per dose, and each composition being free of phyto-estrogenic or progesterone-modulating botanicals, and wherein each composition is provided in a powder, capsule, softgel, or night-time beverage form and chosen for bioavailability optimization.